Once a blockbuster-to-be, Teva finally sounds taps for its PhIII loser laquinimod
This was the year that the old management team at Teva once confidently predicted that its lead drug laquinimod would be approved for multiple sclerosis. Instead, it’s time for the new executive team at the company to finally sound taps for a drug that offered some intriguing signals of efficacy but failed one crucial primary endpoint after the next.
Active Biotech, the Swedish company that out-licensed the drug to Teva 14 years ago for clinical development, put out a note this morning that Teva had returned all rights to the drug, which flopped in multiple Phase III studies for progressive and relapsing/remitting MS as well as a mid-stage trial for Huntington’s disease. The last failure was recorded just a few weeks ago.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.